Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The tumor-specific Ki67 promoter-driven adenovirus replication machinery refers to an engineered genetic construct in oncolytic adenoviruses where the Ki67 promoter, active primarily in proliferating tumor cells, controls expression of the viral E1A gene. This restricts viral replication to Ki67-expressing cancer cells (e.g., renal cell carcinoma), enabling selective tumor cell lysis while sparing normal tissues. Examples include adenoviruses delivering IL-24, IL-15, or decorin under this control for enhanced antitumor effects.
Tumor-specific promoter (Ki67) drives selective adenovirus E1A expression and replication in proliferating cancer cells, leading to oncolysis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor-specific Ki67 promoter-driven adenovirus replication machinery.